Abstract
Patient tissue specimens contain a wealth of potential diagnostic molecular descriptors. Clinical proteomics is a field that combines components of classical protein detection technologies with new technologies to create high-throughput assays that effectively utilize the proteomic information available in the limited sample volumes that are most commonly obtained in the clinical setting. Protein microarrays provide a means for measuring the levels of disease-related proteins extracted from patient tissues, and our laboratory developed the reverse-phase microarray to define the contribution of specific protein activation states to various cancer disease processes. Preservation and stabilization of the in vivo protein signaling architecture is critical for clinical applications, and new tissue fixatives have been recently developed to minimize sources of preanalytical variables. Mass spectrometry, a highly sensitive proteomics tool, is now widely used as an analytical method to discover and catalog disease-related proteins in solid tissues and body fluids such as plasma, serum, and cerebrospinal fluid. Peptidomic and low-molecular-weight proteomics is an important emerging niche in protein biomarker research that requires both analyte concentration and size exclusion simultaneously. New core-shell hydrogel nanoparticles have been developed for one-step, high-throughput low-molecular-weight biomarker concentration, size filtration, and preservation for downstream mass spectrometry analysis and biomarker discovery. Using these new methods, the proteomics field is poised to greatly accelerate tissue and body fluid biomarker discovery, validation, and clinical implementation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Further Reading
Anderson NL, Anderson NG. The human plasma proteome: history character, and diagnostic prospects. Mol Cell Proteomics. 2002;1:845–67.
Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411:355–65.
Celis JE, Gromov P. Proteomics in translational cancer research: toward an integrated approach. Cancer Cell. 2003;3:9–15.
Chaurand P, Caprioli RM. Direct profiling and imaging of peptides and proteins from mammalian cells and tissue sections by mass spectrometry. Electrophoresis. 2002;23:3125–35.
Deutsch EW, Eng JK, Zhang H, et al. Human plasma peptide atlas. Proteomics. 2005;5:3497–500.
Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science. 1996;274:998–1001.
Espina V, Mueller C. Reduction of preanalytical variability in specimen procurement for molecular profiling. Methods Mol Biol. 2012;823:49–57.
Espina V, Wulfkuhle JD, Calvert VS, et al. Laser capture microdissection. Nat Protoc. 2006;1:586–603.
Espina V, Wulfkuhle J, Calvert VS, et al. Reverse phase protein microarrays for theranostics and patient-tailored therapy. Methods Mol Biol. 2008;441:113–28.
Espina V, Mueller C, Edmiston K, et al. Tissue is alive: new technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics Clin Appl. 2009;3:874–82.
Fredolini C, Meani F, Reeder KA, et al. Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by cibacron blue F3G-A loaded hydrogel particles. Nano Res. 2008;1:502–18.
Fredolini C, Meani F, Luchini A, et al. Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. AAPS J. 2010;12:504–18.
Gallagher RI, Silvestri A, Petricoin 3rd EF, et al. Reverse phase protein microarrays: fluorometric and colorimetric detection. Methods Mol Biol. 2011;723:275–301.
Gallagher RI, Blakely SR, Liotta LA, et al. Laser capture microdissection: Arcturus(XT) infrared capture and UV cutting methods. Methods Mol Biol. 2012;823:157–78.
Grubb RL, Deng J, Pinto PA, et al. Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J Proteome Res. 2009;8:3044–54.
Gulmann C, Espina V, Petricoin E, et al. Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res. 2005;11:5847–55.
Gygi SP, Aebersold R. Mass spectrometry and proteomics. Curr Opin Chem Biol. 2000;4:489–94.
Herrmann PC, Gillespie JW, Charboneau L, et al. Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics. 2003;3:1801–10.
Hillenkamp F, Karas M. Mass spectrometry of peptides and proteins by matrix-assisted ultraviolet laser desorption/ionization. Methods Enzymol. 1990;193:280–95.
Knezevic V, Leethanakul C, Bichsel VE, et al. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics. 2001;1:1271–8.
Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411:375–9.
Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA. 2001;286:2211–4.
Longo C, Patanarut A, George T, et al. Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. PLoS One. 2009;4:e4763.
Lowenthal MS, Mehta AI, Frogale K, et al. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem. 2005;51:1933–45.
Luchini A, Geho DH, Bishop B, et al. Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett. 2008;8:350–61.
Meani F, Pecorelli S, Liotta L, et al. Clinical application of proteomics in ovarian cancer prevention and treatment. Mol Diagn Ther. 2009;13:297–311.
Mehta AI, Ross S, Lowenthal MS, et al. Biomarker amplification by serum carrier protein binding. Dis Markers. 2003;19:1–10.
Mueller C, Edmiston KH, Carpenter C, et al. One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. PLoS One. 2011;6:e23780.
Nita-Lazar A, Saito-Benz H, White FM. Quantitative phosphoproteomics by mass spectrometry: past, present, and future. Proteomics. 2008;8:4433–43.
Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001;20:1981–9.
Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002;1:683–95.
Petricoin 3rd EF, Espina V, Araujo RP, et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007;67:3431–40.
Pierobon M, Vanmeter AJ, Moroni N, et al. Reverse-phase protein microarrays. Methods Mol Biol. 2012;823:215–35.
Rosenblatt KP, Bryant-Greenwood P, Killian JK, et al. Serum proteomics in cancer diagnosis and management. Annu Rev Med. 2004;55:97–112.
Silvestri A, Colombatti A, Calvert VS, et al. Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab Invest. 2010;90:787–96.
Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med. 2001;7:493–6.
Tamburro D, Fredolini C, Espina V, et al. Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers. J Am Chem Soc. 2011;133:19178–88.
Wolf-Yadlin A, Sevecka M, MacBeath G. Dissecting protein function and signaling using protein microarrays. Curr Opin Chem Biol. 2009;13:398–405.
Wulfkuhle JD, McLean KC, Paweletz CP, et al. New approaches to proteomic analysis of breast cancer. Proteomics. 2001;1:1205–15.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this entry
Cite this entry
Geho, D.H., Espina, V., Liotta, L.A., Petricoin, E.F., Wulfkuhle, J.D. (2013). Clinical Proteomics in Molecular Genetic Pathology. In: Cheng, L., Zhang, D., Eble, J. (eds) Molecular Genetic Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4800-6_12
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4800-6_12
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-4799-3
Online ISBN: 978-1-4614-4800-6
eBook Packages: MedicineReference Module Medicine